Revenue segments as reported by the company.

BD Medical

BD Life Sciences

BD Interventional

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative

Research and development

Acquisition-related integration and restructuring

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Becton, Dickinson and Co.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

BDX surpasses Q1 expectations, eyes growth amid market challenges

Becton, Dickinson and Co. delivered strong Q1 results, driven by the BD2025 strategy and successful product launches across segments.
While facing challenges in market dynamics and inflationary pressures, the company remains focused on margin expansion and operational efficiency.
Strategic investments, disciplined capital deployment, and a robust pipeline position BD for continued growth and performance improvement in FY 2023.

BDX reports strong Q2 performance, raises guidance for growth

Becton, Dickinson and Co. (BDX) demonstrated robust financial performance and strategic progress in Q2 2023, with raised guidance and a focus on long-term growth.
The company's strengths lie in innovation, efficiency, and sustainability initiatives, while facing challenges in operational execution and macroeconomic factors.
Opportunities for BDX include leveraging M&A for growth, capitalizing on healthcare transformation trends, and meeting long-term targets through sustained performance.
Overall, BDX's performance, strengths, challenges, and opportunities position it for continued success and resilience in the evolving healthcare landscape.

BDX reports robust Q3 earnings, focuses on Alaris system growth

BDX's Q3 earnings call highlighted strong financial performance, progress on BD2025 strategy, and strategic product launches.
The company aims to enhance operational efficiency, improve patient care, and drive revenue growth through innovative solutions.
Despite challenges like market backlog and macroeconomic factors, BD remains focused on long-term targets and margin expansion.

BD reports strong Q4 earnings, eyes growth amid challenges

BD's strong performance in Q4 and FY '23 driven by strategic initiatives and new product launches
Challenges in Q1 and macro environment expected to persist, but opportunities in new product launches and margin improvement
Focus on cash flow, margin improvement, and growth drivers to navigate challenges and drive value creation
Confidence in achieving operating margin guidance and strong performance in FY '24

Becton, Dickinson and Co. exceeds Q1 expectations, eyes growth opportunities

BD's Q1 performance was strong, with a focus on innovation and margin improvement initiatives driving robust cash flows.
Raised FY '24 guidance reflects confidence in revenue growth and margin expansion, despite potential challenges like FX moderation.
Opportunities for growth include market entry in molecular diagnostics and strategic capacity conversion in China.

BDX reports robust Q2 earnings, focuses on innovation and growth

Becton, Dickinson and Co. (BDX) delivered a strong Q2 performance, showcasing robust revenue, margin growth, and innovation. While facing challenges in market dynamics, BD remains focused on achieving its operating margin goal and capitalizing on opportunities for revenue acceleration and margin expansion.

BDX excels in Q3 with strong revenue growth and operational efficiency

Becton, Dickinson and Co. (BDX) showcased robust performance in Q3 2024, driven by organic revenue growth and operational excellence. While facing challenges in market dynamics, the company remains focused on innovation and growth strategies to achieve its financial targets and drive shareholder value.

BDX reports robust Q4 earnings, eyes growth amid market complexities

BDX delivered strong financial performance in Q4 2024, showcasing resilience and strategic focus amidst market challenges.
The company's emphasis on growth initiatives, operational excellence, and shareholder value underscores a commitment to sustainable growth.
While facing challenges such as market uncertainties and integration complexities, BD remains poised to leverage opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs

FRANKLIN LAKES, N.J. , Oct. 13, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will report its fiscal 2022 fourth quarter and full year financial results on Thursday, November 10, 2022.

BD TO ANNOUNCE FISCAL 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Market is undervaluing growth and margin optimization. Recent spinoff of its diabetic line is beneficial.

Becton, Dickinson: Buy In Now While You Can

FRANKLIN LAKES, N.J. , Oct. 11, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today was named to Forbes' 2022 list of the World's Best Employers.

BD Recognized Among World's Best Employers by Forbes

Hormel Foods

The Dividend King index is a collection of just 45 companies with at least 50 consecutive years of dividend growth. These companies have raised payments to shareholders through multiple recessions, showing the strength of their respective business models.

2 Dividend Kings Outperforming the S&P 500 Index

BD's (BDX) latest launch is expected to provide scientists with an integrated ecosystem that enables optimization of panel design, collaboration and analysis.

BD's (BDX) New Cloud Software Solution to Boost Lab Workflow

BD's (BDX) new molecular RUO PCR assay is expected to aid in better managing the ongoing global monkeypox outbreak.

BD's (BDX) Latest Monkeypox PCR Assay Commercially Available

Henry Schein

Public-Private Partnership Supporting Diagnostic Testing in Vulnerable Communities has Provided $2.6 Million to U.S. Clinics Since 2017 to Help Improve Patient Outcomes and Health Equity FRANKLIN LAKES, N.J. , Sept. 29, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, in conjunction with Heart to Heart International (HHI), the National Association of Free and Charitable Clinics (NAFC) and Henry Schein Cares, today announced that six U.S. free and charitable clinics will be awarded product-based grants worth a total of $360,000 to support point-of-care diagnostic testing in communities with underserved and at-risk patient populations.

BD, Heart to Heart International, NAFC and Henry Schein Cares Award Critical Lab Equipment to Six U.S. Free and Charitable Clinics

New  BD® Research Cloud provides scientists with an integrated ecosystem that allows for optimizing panel design, collaboration and analysis FRANKLIN LAKES, N.J. , Sept. 27, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched BD® Research Cloud, a cloud-based software solution designed to streamline the flow cytometry workflow to enable higher quality experiments with faster time to insight for scientists working across a range of disciplines including immunology, virology, oncology and infectious disease monitoring.

BD Launches State-of-the-Art Cloud Software Solution to Streamline Flow Cytometry Research

Research Use Only (RUO) assay now globally available for BD MAX™ System FRANKLIN LAKES, N.J. , Sept. 26, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and CerTest Biotec today announced their newly developed molecular polymerase chain reaction (PCR) assay for monkeypox virus is now commercially available globally, including in the United States, for research use only applications by laboratories.

BD, CerTest Biotec Announce US Commercial Launch of Monkeypox Assay

Eli Lilly

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

There is more to the comparison, and in the sections below, we discuss why we believe BDX stock will offer better returns than LLY stock in the next three years.

This Healthcare Company Is Likely To Offer Better Returns Over Eli Lilly Stock

Livanova

LONDON--(BUSINESS WIRE)-- #livn--LivaNova PLC today announced the LivaNova Board of Directors appointed Brooke Story to the Board, effective September 15, 2022.

LivaNova Board Appoints Brooke Story as a New Director

BD's (BDX) newest product offering is expected to set a new standard in performance for vaccine PFS with new and strict specifications for improved production efficiencies.

BD's (BDX) Latest PFS Launch to Boost Production Efficiencies

BD EffivaxTM Glass Prefillable Syringe Features Enhanced Technology that Builds on Company's Decades of Expertise in the Prefillable Syringe Market and Supports Customers' Manufacturing Needs FRANKLIN LAKES, N.J. , Sept. 13, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today introduced a next-generation glass prefillable syringe (PFS) that sets a new standard in performance for vaccine PFS with new and tightened specifications for processability, cosmetics, contamination and integrity.1 The new BD EffivaxTM Glass Prefillable Syringe has been designed in collaboration with leading pharmaceutical companies to meet the complex and evolving needs of vaccine manufacturing.

BD Launches Next Generation Prefillable Vaccine Syringe Designed for Reliability, Efficiency

Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and strategic deals.

Here's Why You Should Hold on to BD (BDX) Stock for Now

BD had a supply chain risk management solution. It provided good visibility to their Tier 1 suppliers.

BD Chases End-To-End Supply Chain Visibility

Mike Garrison Named EVP and President, Medical segment Rick Byrd Named EVP and President, Interventional segment FRANKLIN LAKES, N.J. , Aug. 25, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of two senior leaders to segment president roles.

BD Promotes Two Senior Executives to Segment Leadership Roles

FRANKLIN LAKES, N.J. , Aug. 24, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 2022 Healthcare Conference on Wednesday, September 7, 2022 at 12:30pm Eastern Time.

BD to Present at the Wells Fargo 2022 Healthcare Conference

FRANKLIN LAKES, N.J. , Aug. 22, 2022 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the consideration payable in connection with its previously announced Tender Offers (as defined below) to purchase for cash up to $500,000,000 aggregate principal amount (which, subject to applicable law, may be increased in the Company's sole discretion, the "Aggregate Offer Cap") of its (i) 3.794% Senior Notes due 2050, (ii) 7.000% Senior Debentures due 2027, (iii) 6.700% Senior Debentures due 2028, (iv) 6.000% Senior Notes due 2039, (v) 5.000% Senior Notes due 2040, (vi) 4.685% Senior Notes due 2044 and (vii) 4.669% Senior Notes due 2047 (collectively, the "Securities" and each a "series"), in the order of priority set forth in the table below (each, an "Acceptance Priority Level"), subject to an aggregate principal amount of each series of Securities that does not exceed the applicable Offer SubCap, if any, set forth in the table below (each, an "Offer SubCap") (collectively, the "Tender Offers"); provided that the Company will only accept for purchase up to an aggregate principal amount of all series of Securities that does not exceed the Aggregate Offer Cap.

BD Announces Pricing of the Tender Offers

FRANKLIN LAKES, N.J. , Aug. 22, 2022 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the early tender results for its previously announced Tender Offers (as defined below) to purchase for cash certain of its outstanding debt securities listed in the table below.

BD Announces Early Tender Results and Upsizing of Offer SubCap

BD's (BDX) tie-up with Accelerate Diagnostics is expected to strengthen the fight to combat the global threat of antimicrobial resistance, thereby boosting patient care.

BD's (BDX) Latest Collaboration to Boost Patient Outcome

BD's (BDX) latest partnership is expected to provide life-changing treatments for cancer and other diseases, thereby improving patient care.

BD (BDX) Ties Up With LabCorp to Boost Patient Outcome

Accelerate Diagnostics

Companies will work together to bring rapid antimicrobial identification and susceptibility diagnostics to more clinicians and patients worldwide FRANKLIN LAKES, N.J. and TUCSON, Ariz.

BD, Accelerate Diagnostics Announce Global Commercial Collaboration

AbbVie

Cigna

DuPont de Nemours

JPMorgan Chase & Co

Pfizer

Buying high-quality blue-chip stocks in a bear market could be a solid path to generating lucrative long-term returns. Blue-chip stocks are typically large-cap businesses in the mature stage of their business cycle.

7 Blue-Chip Stocks That Will Survive 2022

Labcorp Holdings Inc

Companies combine key capabilities to advance flow cytometry as an essential companion diagnostic modality for cancer and other diseases FRANKLIN LAKES, N.J. , Aug. 9, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration agreement with Labcorp (NYSE: LH), a leading global life sciences company, creating a framework to develop, manufacture, market and commercialize flow cytometry-based companion diagnostics (CDx) intended to match patients with life-changing treatments for cancer and other diseases.

News for Becton, Dickinson and Co. Stock (BDX)